Roche looks to expand and upgrade US research centers as part of $50B investment strategy in the country

Title

Roche Unveils $50 Billion U.S. Expansion:
Major Upgrades and New Research Centers Across Eight States

Roche has announced a $50 billion investment strategy to expand and upgrade its U.S. research centers and manufacturing operations over the next five years2 5.
This expansion includes new and upgraded R&D facilities in Arizona, Indiana, and California, as well as new manufacturing plants in Pennsylvania, Indiana, and a location yet to be determined3 4.

- Planned facilities include:

A gene therapy manufacturing site in Pennsylvania4 5.
A 900,000-square-foot manufacturing center to support Roche's portfolio of next-generation weight-loss medicines, location TBD1 5.
A new plant in Indiana focused on continuous glucose monitoring device production1 5.
An AI-focused R&D hub in Massachusetts4.
- Roche currently operates 13 manufacturing and 15 R&D sites across eight states, employing over 25,000 people in the U.S.5.
- The investment is expected to generate 1,000 new direct jobs at Roche and over 11,000 additional jobs at partnering companies, including nearly 6,500 construction jobs5.
- This large-scale expansion is partially in response to looming tariffs on biopharma products4 5.
- Roche plans to grow its weight-loss treatment offerings via a $5.3 billion collaboration with Zealand Pharma for the co-development of petrelintide, targeting overweight and obesity indications5.